Navigation Links
Simeprevir Administered Once Daily as Part of Combination Therapy Demonstrates Sustained Virologic Response in Treatment-Naive and Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
Date:11/2/2013

60;
In the pivotal Phase 3 PROMISE study, 79 percent of treatment-experienced hepatitis C patients treated with simeprevir in combination with pegylated interferon and ribavirin who previously experienced a relapse after prior treatment with pegylated interferon-based therapy achieved the primary endpoint of SVR12 compared to 37 percent of patients treated with placebo plus pegylated interferon and ribavirin. In this sub-analysis, 65 percent of patients with the IL28B TT genotype, 74 percent of patients with a METAVIR score of F4 and 70 percent of patients with genotype 1a HCV treated with simeprevir combined with pegylated interferon and ribavirin achieved SVR12 compared to 19 percent, 26 percent and 28 percent of patients taking placebo plus pegylated interferon and ribavirin, respectively. Among patients with the genotype 1a Q80K polymorphism at baseline, 47 percent of patients treated with simeprevir combined with pegylated interferon and ribavirin achieved SVR12 compared to 30 percent of patients treated with placebo in combination with pegylated interferon and ribavirin.

The most common adverse events in patients treated with simeprevir combined with pegylated interferon and ribavirin in the first 12 weeks were fatigue, headache and influenza-like illness. Three percent and 18 percent of patients treated with simeprevir combined with pegylated interferon and ribavirin experienced on-treatment failure and relapse, respectively, compared to 27 percent and 34 percent of patients taking placebo plus pegylated interferon and ribavirin, respectively.

"We are very proud of the depth and breadth of our clinical trial program," said Gaston Picchio, Disease Area Leader Hepatitis, Janssen Research & Development. "Following last week's positive vote from the FDA's Antiviral Drugs Advisory Committee to recommend approval of simeprevir, we look forward to making simeprevir available to patients living with chronic
'/>"/>

SOURCE Janssen R&D Ireland
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Simeprevir Data in Hepatitis C Patients to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
2. Primary Efficacy and Safety Findings from Phase 3 Study of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
3. U.S. FDA Grants Priority Review to Simeprevir (TMC435) for Combination Treatment of Genotype 1 Chronic Hepatitis C
4. Janssen and Johnson & Johnson to Provide Webcast Presentation of Simeprevir Phase 3 Clinical Data Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
5. Findings from Two Phase 3 Studies of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients
6. Janssen Submits New Drug Application to U.S. FDA for Simeprevir (TMC435) for Combination Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C
7. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
8. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
9. MCOs Shifting Control Over Office-Administered Products from Medical to Pharmacy Benefit, Particularly Affecting Rheumatoid Arthritis Therapies
10. American Journal of Medicine Publishes Hypertension Study Comparing the Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone versus Azilsartan Medoxomil Co-administered with Hydrochlorothiazide
11. Daiichi Sankyos Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 31, 2015  Qualcomm Incorporated (NASDAQ: QCOM ... Life, Inc., is collaborating with Davita Healthcare ... solutions powered by Qualcomm Life,s 2net™ Device Connectivity ... continuous care, informed interventions and better management of ... Life,s annual Connect 2015 ecosystem conference ...
(Date:8/31/2015)... WOODCLIFF LAKE, N.J. and STAMFORD, ... the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and ... into a worldwide collaboration agreement for the development and ... a dual orexin receptor antagonist entering Phase III clinical ... Under the terms of the agreement, Eisai and Purdue ...
(Date:8/30/2015)... , August 31, 2015 ... healthbank to deliver ... the world,s first citizen-owned health data transaction platform, announced ... Netcetera to engineer and bring to market ... (Logo: http://photos.prnewswire.com/prnh/20150828/261966) , "Our business model is ...
Breaking Medicine Technology:Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 2Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 3Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 4Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 5Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5healthbank Announces Strategic Partnerships to Bring to Market Global Health Data Transaction Platform 2healthbank Announces Strategic Partnerships to Bring to Market Global Health Data Transaction Platform 3healthbank Announces Strategic Partnerships to Bring to Market Global Health Data Transaction Platform 4
... Ill., Nov. 4, 2011 Life Spine, a medical ... for the surgical treatment of spinal disorders, announced today ... its most profitable month in its history. As a ... from the occiput to the sacrum. Aileron™, ...
... 4, 2011 SCRIP, a leading global pharmaceutical ... for its business excellence and innovative R & D capabilities. ... the Who,s Who of the world pharmaceutical industry on November ... & , Best   Overall Pipeline, recognitions for ...
Cached Medicine Technology:Glenmark Wins Two Prestigious Global Recognitions at SCRIP Awards 2011 2
(Date:8/31/2015)... ... 31, 2015 , ... Nine innovative healthcare companies (listed below) ... Healthcare(SM) Awards Event , on October 21, 2015, in Long Beach. The Event, ... and individuals who are dramatically reducing the cost of quality healthcare. , The ...
(Date:8/31/2015)... ... August 31, 2015 , ... Finnleo , a leader in the ... in the 3rd quarter, the newly re-styled and re-designed “Hallmark Series” updates the Passport ... These new models include more glass and a more upscale feel than the current ...
(Date:8/31/2015)... ... , ... The more hours young adults spend watching television each day, the ... circumference, a 15-year analysis by the University of Pittsburgh Graduate School of Public Health ... young adulthood is an important time to intervene and promote less television viewing, according ...
(Date:8/31/2015)... ... ... On Saturday, May 30th, 2015, Best Drug Rehabilitation sponsored a benefit concert known ... purpose behind this concert was to raise money for music education programs in the ... of “Music with a Mission” helped with a portion of the cost of holding ...
(Date:8/31/2015)... ... August 31, 2015 , ... "While working as an ... effectively deliver oxygen with a lower risk of failure," explained an inventor, from ... the Adam Device." , The Adam Device offers a quick, effective and predictable ...
Breaking Medicine News(10 mins):Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 2Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 3Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 4Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 5Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 6Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 7Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 8Health News:Finnleo Introduces Hallmark Series Saunas 2Health News:Watching More TV as a Young Adult Predicts Obesity 2Health News:Watching More TV as a Young Adult Predicts Obesity 3Health News:2015 "Music With A Mission" Sponsor Best Drug Rehabilitation Releases Artist Compilation Video 2Health News:2015 "Music With A Mission" Sponsor Best Drug Rehabilitation Releases Artist Compilation Video 3Health News:InventHelp® Client's Invents Medical Device to Restore Respiratory Function (BGF-905) 2
... MONTREAL, June 11 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX : ... ended April 30, and reports on its recently concluded ... Stategic Collaboration , , As previously announced on ... entered into a strategic collaboration which provides Angiotech with ...
... Continued Market Share Increase Combined with Significant Operating Efficiencies Lead to ... Cord Blood Registry (CBR), the global leader in ... blood, reported solid revenue growth in first quarter 2009, up nearly ... quarter showed even stronger gains due to increases in both volume ...
... ... for the quarter ending April 30, 2009. With consistent growth and increased orders, ... ... -- Clearly Contacts released their second quarter unaudited financial results today, for the ...
... ... savings for surgical instrument repairs. , ... Stow, OH (PRWEB) June 11, 2009 -- Spectrum Surgical Instruments is ... any model of surgical instrument and each repair is backed by our 100% Satisfaction ...
... U.S. House of Representatives voted 235-187 to approve H.R. ... new "Office for Global Women,s Issues" and directs that ... around the world. Secretary of State Hillary Clinton ... administration "will protect the rights of women, including their ...
... NORTH HOLLYWOOD, Calif., June 10 IPC The Hospitalist Company, Inc. ... company, announced today that management is scheduled to present at the ... in New York City. Adam Singer, M.D., Chairman and CEO, ... conference. IPC,s presentation will take place at 3:15 P.M. Eastern ...
Cached Medicine News:Health News:Haemacure Reports on Strategic Collaboration with Angiotech Pharmaceuticals, Inc. and Second Quarter 2009 Financial Results 2Health News:Haemacure Reports on Strategic Collaboration with Angiotech Pharmaceuticals, Inc. and Second Quarter 2009 Financial Results 3Health News:Haemacure Reports on Strategic Collaboration with Angiotech Pharmaceuticals, Inc. and Second Quarter 2009 Financial Results 4Health News:Cord Blood Registry Maintains Solid Growth in First Quarter 2009 2Health News:Cord Blood Registry Maintains Solid Growth in First Quarter 2009 3Health News:Clearly Contacts Announces Another Quarter Of Growth In The Economic Downturn 2Health News:Clearly Contacts Announces Another Quarter Of Growth In The Economic Downturn 3Health News:Three-Year Agreement for Surgical Instrument Repair Services 2Health News:IPC The Hospitalist Company, Inc. to Present at Jefferies 3rd Annual Healthcare Conference 2
Inquire...
... Small Bone Power System combines precision ... under the most exacting conditions. The ... small bone osteotomies and oral/maxillofacial procedures ... Length Available), Oscillating Saw (Extended Length ...
... System is a specialized electric system ... designed for use in Otolaryngology, Neurosurgery, ... System consists of a specialized electric ... designed to provide precision and control ...
... The Brasseler USA™ Battery ... quickly and efficiently determine ... STR-2000, STR-3000 Extended Run, ... Driver™, Battery Packs contain ...
Medicine Products: